Investors and Collaborators
Mesophotonics completed its first round financing in July 2001
by securing £2.4 million from BTG.
Second round funding of £5.5 million was completed in December
2003. Quester led the investment with participating
investors Auriga Partners (Paris), NIF
Ventures Co. Ltd (Tokyo) and existing investor BTG.
Quester is one of the UK's leading independent venture capital
groups specialising in the provision of finance and management support
for growth companies at all stages of their life. Quester’s
focus is on early stage investments in information and communication
technology, healthcare and life science companies. With its first
rate track record, Quester has earned a reputation as one of the
best UK based sources of venture capital. The Quester investment
team manages approximately £300 million on behalf of major
institutional investors, leading UK universities, and five quoted
venture capital trusts.
For further information please refer to www.quester.co.uk
Auriga Partners is a French independent early stage VC fund. Auriga
focuses on investments in high potential innovative start ups in
the areas of Life Sciences and Information Technology, mainly in
Europe. To date Auriga manages about €200M funds split between
3 funds: European Medical Ventures, Auriga Ventures I and Auriga
Ventures II. For further information please refer to www.aurigapartners.com
BTG finds, develops and commercialises emerging technologies in
the life and physical sciences. These innovations are protected
by a strong portfolio of intellectual property that BTG develops
and enhances. BTG then captures the value in these technologies
through licensing and venturing activities. From the origins of
its business in 1949, BTG has commercialised major innovations such
as Magnetic Resonance Imaging (MRI), recombinant factor IX blood-clotting
protein, Campath® (alemtuzumab) and Multilevel Cell (MLC) memory.
BTG is quoted on the London Stock Exchange under the symbol “BGC”
and operates from offices in London and Philadelphia, with representation
in Tokyo. BTG operates through wholly owned subsidiaries, BTG International
Ltd. and BTG International Inc. in the UK and USA, respectively.
Further information on BTG can be found at www.btgplc.com
NIF Ventures Co Ltd is the venture capital arm of the Daiwa Securities
Group of Japan. NIF manages approximately $1 billion in venture
capital funds and has funded over 1,500 companies and assisted over
450 companies to exit since its foundation in 1982. Its primary
focus is in information and communications technologies and life
science VC investments. With offices in Japan, Taiwan, Singapore,
and the United States, NIF offers worldwide representation.
Further information on NIF can be found at www.nif.co.jp
About The University of Southampton
The University of Southampton is a leading UK teaching and research
institution with a global reputation for leading-edge research and
scholarship. The University, which celebrated its Golden Jubilee
in 2002, has 20,000 students and over 4,500 staff and plays an important
role in the City of Southampton. Its annual turnover is in the region
of £235 million.($425 million).
Further information can be found at : www.soton.ac.uk